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(95%CI: $U.S.334 to $U.S.856) per dose of IV and SC bortezomib. Over a full cycle of 
therapy (i.e. 4 doses), the total cost for drug delivery including wastage and drug 
acquisition would be substantial at $U.S.7,113 and $U.S.6,327 for IV and SC bort-
ezomib respectively. ConClusions: SC bortezomib resulted in a significant savings 
in drug delivery resources. However, drug wastage remained an important factor, 
regardless of the route of administration.
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objeCtives: Analyses were conducted on Republic of Srpska (RS) Health Insurance 
Fund (HIF) national prescription database. Analyses explored health expenditure 
in pharmaceutical consumption of oncology medications for the fiscal year 2005 
through 2012, in order to determine impact of introduction of public tenders in 
2008. RS HIF provides coverage for a population of 1.2 million. Methods: RS HIF 
national prescription database was explored. Key cost drivers and the differences 
were identified across all medications covered by the RS HIF. Results: In 2005, total 
expenditure for all Oncology medication was € 1.2 million. In 2012, total expenditure 
for all Oncology medications was € 8 million. This increase of 681% is a result of two 
critical factors: 1) a national policy shift in 2004, of patient treatment switch from 
being treated abroad in Republic of Serbia to being locally treated; 2) exponential 
increase in Oncology indications incidence. In 2008 there was an introduction of 
public tenders that run every two calendar years, which allowed additional medi-
cations to be purchased by the RS HIF, as well at lower costs and hence it resulted 
in moderate decrease in expenditures, even though there was a steady increase in 
quantities purchased. This resulted in balanced and average expenditure from 2008 
to 2012 of € 9 million. Based on 2005 through 2012 consumption of Oncology medica-
tions, it is derived that over the years to date, top three Oncology indications are: a) 
Metastatic breast cancer, b) Metastatic colorectal cancer, c) Colorectal cancer Stage 
III. ConClusions: Results indicate that most of the patients treated abroad, trans-
ferred back to RS HIF for treatment by 2008. Top three Oncology indications show 
that there is a need for higher public awareness and patient education in RS related 
to them. This is in line with current RS public health care policies and strategies.
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objeCtives: Public health systems need to make well-founded choices in order to 
distribute their scarce resources in the most efficient way. Given the large number 
of cancer patients and their increasing life expectancy, public/private investments 
in oncology research, the growing launches of new anticancer agents and con-
sequent high budget impact of cancer care, market access of cancer drugs has 
become delicate over the last decade. Furthermore, decision makers are challenged 
by ethical considerations and endeavor after fair and equal access to treatments 
for cancer patients. The aim of this study is to generate an overview of price set-
ting and reimbursement procedures for cancer drugs in eight European coun-
tries. Methods: Belgium, The Netherlands, France, Germany, Italy, Poland, UK and 
Sweden were selected as the countries of interest. Results were collected between 
January and March 2013 through a literature review and a qualitative question-
naire sent to authorities involved in price setting and reimbursement of drugs. 
The specific section of results for each country was validated by experts in the 
field. Results: Diverse measures are introduced to optimize market access of can-
cer drugs such as adjusted cost-effectiveness thresholds and new market access 
agreements. Additionally, innovative cancer drugs are excluded from explicit cost 
control measures in some of the studied countries. Given the fact that each drug 
covered by the limited public health care budget might possibly exclude another 
one from reimbursement, results suggest preferential treatment of cancer drugs 
compared to drugs for other diseases. Besides societal preferences for treatments 
of severe diseases, there is no solid evidence that could justify prioritization of can-
cer. ConClusions: Price setting and reimbursement procedures seem to prioritize 
cancer above other disease areas. Further research needs to address the question if 
society attributes higher value to cancer drugs than to treatments for other diseases.
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objeCtives: CRPC is an advanced form of prostate cancer with poor prognosis. 
The changing treatment landscape calls for use of real-world data to provide cur-
rent information on disease epidemiology, treatment patterns, comparative effec-
tiveness, and treatment cost. Administrative claims databases are a rich source of 
real-world data; however, they lack clinical values needed to identify CRPC patients. 
As currently there is no standard method to identify CRPC patients when clinical 
variables are unavailable, we developed and validated an algorithm using claims 
data to reliably identify CRPC patients. Methods: Male patients with an ICD-9 
code for PC between January 1, 2004 and November 30, 2012 were identified from 
IMS pharmacy and medical claims data. Metastatic PC was identified by additional 
tumors on or after the PC diagnosis. Surgical castration was determined using CPT 
and ICD-9 procedure codes for orchiectomy; medical castration was identified using 
codes for hormone therapies. The algorithm identified patients as having CRPC 
if they had any of the following: 1) switch in hormone therapy; 2) new metasta-
ses while on hormone therapy; 3) switch in treatment from any hormone therapy 
PCN196
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objeCtives: Costs of cancer treatment has received increased attention in the last 
decade mainly because of the very high expenses on new biological drugs. Total 
cancer treatment costs vary by tumor type and stage, with the highest costs usually 
incurring in the last year of life. In this study, we characterized the drugs that have 
the highest budget-impact in treating cancer patients in Israel, immediately before 
death. Methods: Clalit Health Services (CHS), Israel’s largest health-care organiza-
tion with over 4 million members, serves 52% of the total population. Using CHS’s 
comprehensive databases, we identified the three leading fatal cancers in 2012. We 
calculated CHS’s acquisition costs for all pharmaceuticals provided to patients in 
their last three months of life, and extracted the top budget-consuming drugs used 
during this period. Results: The leading fatal cancers in 2012 were colorectal (1551 
deaths), breast (1273) and lung cancer (1174). The drugs with the highest budget-
impact in colorectal cancer patients were (% of total drug-expenditure, # of patients 
treated (% of the total number of patients)): Cetuximab (20.2%, 38 patients (2.5%)), 
Bevacizumab (14.6%, 56 patients (3.6%)), Panitumumab (6.6%, 21 patients (1.4%), 
Fentanyl (6.5%, 278 patients (17.9%)), Irinotecan (4.0%, 77 patients (5.0%)). In breast 
cancer: Trastuzumab (12.0%, 23 patients (1.8%)), Fulverstant (6.4%, 42 patients (3.3%), 
Fentanyl (5.9%, 178 patients (14.0%)), Lapatinib (5.5%, 10 patients (0.8%)), Zoledronic 
acid (4.1%, 59 patients (4.6%)). In lung cancer: Erlotinib (21.4%, 77 patients (6.6%)), 
Gefitinib (12.8%, 42 patients (3.6%)), Pemetrexed (10.5%, 57 patients (4.9%)), Crizotinib 
(6.0%, 8 patients (0.7%)), Fentanyl (4.5%, 298 patients (25.4%)). ConClusions: A 
significant proportion of the pharmaceutical budget was spent on a relatively small 
portion of patients who received expensive novel targeted therapies during their last 
months of life although chances for success were minimal. A much higher portion 
of patients received palliative treatments for a substantially smaller proportion of 
the pharmaceutical expenditure.
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objeCtives: To demonstrate real-world benefits of biosimilar quota system used 
in Germany. Methods: Long before recent economic challenges health care costs 
have represented a vast and unsustainable trajectory beyond western economies 
real GDP. Biologics have become a driver of payer expenditure with an 83% increase 
in global spend expected from 2010 to 2020. The introduction of biosimilars since 
2006 represents an opportunity to reduce expenditure on biologics while maintain-
ing the quality of patient care. Uptake of biosimilars and associated cost savings has 
been very different across markets. One mechanism, to encourage utilization of bio-
similars, is to introduce quota style systems as in Germany. Using claims data from 
the KV regions to determine the use of biosimilar epoetin in relation to the quotas 
introduced by the 17 physician based regions in Germany, and the historic spend 
on epoetin treatment to calculate the budget expenditure reduction. Results: 
Driven by the German quota system together with consultancy via KV- and SHI-
pharmacists and physicians, biosimilar epoetins in Germany have obtained 57% 
of the German EPO market by Q3 2012. A reduction of 51% was experienced across 
historic public prices from January 2007 to August 2011. The increased penetration 
of biosimilar epoetin resulted in cumulative savings in Germany of € 551 million. 
German real-world research demonstrated that biosimilar epoetin treatments did 
not experience any significant differences in efficacy and safety when compared 
with the originator. ConClusions: The quota system has become a significant 
driver of biosimilar epoetin uptake in Germany, which has resulted in substantial 
cumulative savings to the German health care system. Additionally this has allowed 
for extensive clinical experience with biosimilars which resulted in confirmation of 
the expected efficacy and safety outcomes. The biosimilar quota system provides 
markets with a mechanism to reduce biologic expenditure, increase patient access 
to biologic medicines and increase physician experience.
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objeCtives: Bortezomib is an effective therapy for patients with MM. The rec-
ommended dosage is 1.3 mg/m2 IV dosed on days 1, 4, 8 and 11 for eight, three 
week cycles. However, a recent randomized non inferiority trial demonstrated that 
the same dosage of bortezomib administered SC is equally effective, but with an 
improved safety profile. To measure the overall efficiency and cost savings of the SC 
route, a prospective time and motion study was undertaken in MM patients treated 
in a sample of U.S. community oncology clinics. Methods: Time and motion and 
resource use data were collected from MM patients being treated with bortezomib 
IV (n= 20) or SC (n= 20) in seven U.S. community oncology clinics. Resource use 
and time impact on clinical staff were quantified using unit cost estimates. This 
included costs for drug preparation, wastage, administration, materials and sup-
plies, premedication, patient chair time and all labor costs. Results: The mean 
total time for IV and SC delivery (preparation, administration and total chair time) 
was 76.3 and 39.8 minutes (p = 0.005), with the associated (i.e. drug preparation and 
administration) cost being $U.S.189 and $U.S.90.84 respectively. With the inclusion 
of costs for drug wastage (i.e. mean of 1.2 mg for both IV and SC bortezomib, which 
is 34% of a 3.5 gram vial and costs approximately $U.S.500) and premedication, 
the cost for drug delivery was $U.S.808 (95%CI: $U.S.603 to $U.S.1011) and $U.S.596 
